Solara Active Pharma Sciences (NSE:SOLARA) Debt-to-EBITDA : N/A (As of Jun. 2026)

Solara Active Pharma Sciences  (NSE:SOLARA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Solara Active Pharma Sciences Debt-to-EBITDA Related Terms

The historical data trend for Solara Active Pharma Sciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solara Active Pharma Sciences Debt-to-EBITDA Chart

Solara Active Pharma Sciences Annual Data
	Trend	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22	Mar23	Mar24	Mar25	Mar26
Debt-to-EBITDA		Get a 7-Day Free Trial					11.48	6.65	-3.58	3.79	3.67

Solara Active Pharma Sciences Quarterly Data
	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26	Jun26
Debt-to-EBITDA	Get a 7-Day Free Trial															N/A	3.17	N/A	3.67	N/A

NSE:SOLARA vs ZTS: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Solara Active Pharma Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Solara Active Pharma Sciences Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Solara Active Pharma Sciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Solara Active Pharma Sciences's Debt-to-EBITDA falls into.

Solara Active Pharma Sciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Solara Active Pharma Sciences's Debt-to-EBITDA for the fiscal year that ended in Mar. 2026 is calculated as

Solara Active Pharma Sciences's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Solara Active Pharma Sciences Business Description